---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-283861"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2025-11-17T23:59:59+00:00"
generated_at: "2026-05-16T19:16:54.047680+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics appoints Kristian Humer as CFO effective Nov 17, 2025

## Summary
- Kristian Humer, formerly CFO at Foghorn Therapeutics and Viridian Therapeutics, joins as CFO and Principal Financial Officer.
- Compensation includes $520K base salary, 40% target bonus, option for 480K shares, and $100K sign-on bonus paid in two installments.
- Severance: 9 months base salary + COBRA if terminated w/o cause or for good reason; 12 months + COBRA plus full equity acceleration if within 12 months of a change in control.

## SEC filing metadata
- accession: 0001193125-25-283861
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2025-11-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312525283861/0001193125-25-283861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312525283861/d14139d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-283861
- JSON: https://secwatch.observer/filing/0001193125-25-283861.json
- Plain text: https://secwatch.observer/filing/0001193125-25-283861.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.